Evidence-based decision making: when should we wait for more information?
- PMID: 18997223
- DOI: 10.1377/hlthaff.27.6.1642
Evidence-based decision making: when should we wait for more information?
Abstract
We discuss the challenge of managing innovation in and access to health care interventions in an evidence-based, cost-effective way, and we describe a decision-making framework (using U.S. and U.K. case studies) for health care payers considering the adoption of new technologies. We argue that providing reimbursement for what could be a cost-effective technology "only in the context of research" will be appropriate if the costs of delaying implementation are offset by the value of "keeping one's options open" by waiting for more information. We conclude that there is a need for better integration of health care decision-making processes with research policies.
Comment in
-
Buying new technology.Health Aff (Millwood). 2008 Nov-Dec;27(6):1619. doi: 10.1377/hlthaff.27.6.1619. Health Aff (Millwood). 2008. PMID: 18997220 No abstract available.
Similar articles
-
A rational framework for decision making by the National Institute For Clinical Excellence (NICE).Lancet. 2002 Aug 31;360(9334):711-5. doi: 10.1016/S0140-6736(02)09832-X. Lancet. 2002. PMID: 12241891
-
Outcomes of adoption: measuring evidence uptake by individuals and organizations.Worldviews Evid Based Nurs. 2004;1 Suppl 1:S41-51. doi: 10.1111/j.1524-475X.2004.04048.x. Worldviews Evid Based Nurs. 2004. PMID: 17129334 Review.
-
Guidelines and Value-Based Decision Making: An Evolving Role for Payers.N C Med J. 2015 Sep-Oct;76(4):243-6. doi: 10.18043/ncm.76.4.243. N C Med J. 2015. PMID: 26509518
-
Applying research to health care policy and practice: medical and managerial views on effectiveness and the role of research.J Health Serv Res Policy. 2000 Apr;5(2):103-8. doi: 10.1177/135581960000500208. J Health Serv Res Policy. 2000. PMID: 10947544
-
Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.Pharmacoeconomics. 2010;28(2):113-42. doi: 10.2165/11530820-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085389 Review.
Cited by
-
Exploring the misalignment on the value of further research between payers and manufacturers. A case study on a novel total artificial heart.Health Econ. 2022 Sep;31 Suppl 1(Suppl 1):98-115. doi: 10.1002/hec.4520. Epub 2022 Apr 23. Health Econ. 2022. PMID: 35460307 Free PMC article.
-
Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2019 Oct;37(10):1195-1207. doi: 10.1007/s40273-019-00792-7. Pharmacoeconomics. 2019. PMID: 30895564 Free PMC article. Review.
-
Department of Health Research-Health Technology Assessment (DHR-HTA) database: National prospective register of studies under HTAIn.Indian J Med Res. 2018 Sep;148(3):258-261. doi: 10.4103/ijmr.IJMR_1613_18. Indian J Med Res. 2018. PMID: 30425215 Free PMC article. No abstract available.
-
Value of Information Analysis Informing Adoption and Research Decisions in a Portfolio of Health Care Interventions.MDM Policy Pract. 2016 Jul 7;1(1):2381468316642238. doi: 10.1177/2381468316642238. eCollection 2016 Jul-Dec. MDM Policy Pract. 2016. PMID: 30288400 Free PMC article.
-
The AAN's role in the development of health insurer coverage policy.Neurol Clin Pract. 2012 Jun;2(2):139-145. doi: 10.1212/CPJ.0b013e31825a722b. Neurol Clin Pract. 2012. PMID: 29443327 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
